Physician profile
Andrew D Krasnoff
NPI 1528158300
$4,915.71
in general payments reported to CMS, 2019-2025
28 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 96% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $154 · 2021: $278 · 2022: $359 · 2023: $676 · 2024: $1,613 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $777.62 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $518.14 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $501.84 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Glaxosmithkline, LLC. | $467.19 | 2019-2025 | Penmenvy, Bexsero |
| Novo Nordisk INC | $339.40 | 2024-2025 | Wegovy |
| Kaleo, INC. | $324.65 | 2019-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $308.20 | 2024-2025 | Dupixent |
| Sanofi Pasteur INC. | $294.90 | 2019-2025 | |
| Tris Pharma INC | $248.30 | 2019-2025 | Quillivant, Dyanavel Xr, Quillichew Er |
| Cranial Technologies, INC | $184.37 | 2019-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $161.89 | 2024-2025 | |
| Pfizer INC. | $148.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.02 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $76.89 | 2025 | Jornay Pm |
| Abbott Laboratories | $69.21 | 2023-2025 | Id Now Instrument |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $56.04 | 2025 | Ycanth |
| Alk-Abello, INC | $45.61 | 2025 | Neffy |
| Noven Therapeutics, LLC | $45.03 | 2025 | Xelstrym |
| Neos Therapeutics, Lp | $29.90 | 2025 | Cotempla Xr-Odt |
| Vertical Pharmaceuticals, LLC | $28.38 | 2019-2025 | Relexxii |
| Ultragenyx Pharmaceutical INC. | $23.66 | 2021 | |
| Arbor Pharmaceuticals, INC. | $22.39 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $21.03 | 2024 | Flumist Quadrivalent |
| Seqirus USA INC | $20.61 | 2023 | Flucelvax Quadrivalent |
| Lnhc, INC | $19.88 | 2025 | Zelsuvmi |
| Genentech USA, INC. | $19.09 | 2019 | |
| Cognoa, INC. | $15.33 | 2022 | |
| Adlon Therapeutics L.P. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Krasnoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.